tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

LifeMD Reschedules Q3 Earnings Call Amid Revenue Adjustments

Story Highlights
  • LifeMD rescheduled its Q3 2025 earnings release to November 17 due to revenue recognition corrections.
  • The $4.6 million adjustments will not materially affect revenue results or cash flow.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
LifeMD Reschedules Q3 Earnings Call Amid Revenue Adjustments

Meet Your ETF AI Analyst

LifeMD ( (LFMD) ) has shared an announcement.

On November 5, 2025, LifeMD announced the rescheduling of its third quarter 2025 earnings release and conference call to November 17, 2025, due to corrections identified in revenue recognition related to past data system migrations. The adjustments, impacting approximately $4.6 million or 1.4% of cumulative revenue, will not materially affect reported revenue results or the company’s cash flow and position. This decision reflects LifeMD’s commitment to accurate financial reporting and transparency, ensuring stakeholders are informed of the necessary adjustments without significant operational impact.

The most recent analyst rating on (LFMD) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on LifeMD stock, see the LFMD Stock Forecast page.

Spark’s Take on LFMD Stock

According to Spark, TipRanks’ AI Analyst, LFMD is a Neutral.

LifeMD’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue growth and high leverage. Technical analysis indicates bearish momentum, further weighing down the score. While the earnings call provided some positive insights, such as telehealth growth and strategic initiatives, these are offset by operational challenges and revised guidance. The valuation remains unattractive due to ongoing losses.

To see Spark’s full report on LFMD stock, click here.

More about LifeMD

LifeMD, Inc. is a leading provider of virtual healthcare services and pharmacy, offering telemedicine, laboratory and pharmacy services, and specialized treatment across over 200 conditions, including primary care, men’s and women’s health, mental health, and weight management. The company utilizes a vertically integrated digital care platform and a 50-state affiliated medical group to enhance access to high-quality and affordable care.

Average Trading Volume: 1,473,671

Technical Sentiment Signal: Hold

Current Market Cap: $257M

Learn more about LFMD stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1